New Potential Therapies for Chronic Hepatitis B

Sun Hong Yoo and Jung Hyun Kwon

doi:10.4166/kjg.2019.74.5.267

HOME > Articles >

Korean J Gastroenterol < Volume 74(5); 2019 < Articles

Korean J Gastroenterol 2019; 74(5): 267-273 https://doi.org/10.4166/kjg.2019.74.5.267

New Potential Therapies for Chronic Hepatitis B

Sun Hong Yoo and Jung Hyun Kwon

Department of Internal Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea

Correspondence to: Jung Hyun Kwon, Department of Internal Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 56 Dongsu-ro, Bupyeong-gu, Incheon 21431, Korea. Tel: +82-32-280-5886, Fax: +82-32-280-5023, E-mail: doctorkwon@catholic.ac.kr, ORCID: https://orcid.org/0000-0002-5484-5864

Received: October 12, 2019; Revised: October 23, 2019; Accepted: October 25, 2019; Published online: November 25, 2019.

This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract: A HBV infection is a dynamic disease and long-term liver inflammation contributes to the development of liver cirrhosis and hepatocellular carcinoma. Currently available nucleos(t)ide analogues and pegylated interferon are effective in inhibiting HBV replication but rarely achieve HBsAg clearance. The present article introduces a new definition of HBV cure and several emerging therapies for HBV cure, including direct acting antivirals and immune modulatory antivirals.; Keywords: Hepatitis B virus; Therapeutics